top of page

DEMETHER

PHASE II TRIAL OF TRASTUZUMAB AND PERTUZUMAB MAINTENANCE AFTER T-DXD INDUCTION FOR HER2+ UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER

TRIAL RESUME

home_fondo_you_barra.jpg
DEMETHER.jpg

CLINICAL TRIAL DETAILS

A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL EXPLORING THE MAINTENANCE OF TRASTUZUMAB AND PERTUZUMAB FOLLOWING TRASTUZUMAB DERUXTECAN AS INDUCTION TREATMENT FOR HER2-POSITIVE UNRESECTABLE LOCALLY RECURRENT OR METASTATIC BREAST CANCER PATIENTS (DEMETHER). 

 
DEMETHER AT CLINICALTRIALS.GOV

Breast Cancer

II

165

TBC

TBC

Start Up

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

bottom of page